Oxford BioTherapeutics said Thursday that it has extended its second collaboration with Boehringer Ingelheim for another two years. The biotech said that the extension will add more programs to allow for developing “novel cancer immunotherapies” in indications with a higher unmet need.
The San Jose, CA-based biotech...
